AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $944,000 | +317.7% | 18,665 | +284.8% | 0.00% | – |
| Q2 2023 | $226,000 | +78.0% | 4,850 | +45.9% | 0.00% | – |
| Q1 2023 | $127,000 | -56.5% | 3,325 | -37.4% | 0.00% | – |
| Q4 2022 | $292,000 | +228.1% | 5,312 | +103.9% | 0.00% | – |
| Q3 2022 | $89,000 | +304.5% | 2,605 | +9.9% | 0.00% | – |
| Q2 2022 | $22,000 | -58.5% | 2,370 | -37.5% | 0.00% | – |
| Q1 2022 | $53,000 | -67.1% | 3,793 | -50.2% | 0.00% | – |
| Q4 2021 | $161,000 | +66.0% | 7,623 | +74.6% | 0.00% | – |
| Q3 2021 | $97,000 | -2.0% | 4,365 | +9.9% | 0.00% | – |
| Q2 2021 | $99,000 | +28.6% | 3,972 | +49.8% | 0.00% | – |
| Q1 2021 | $77,000 | +60.4% | 2,652 | +44.8% | 0.00% | – |
| Q4 2020 | $48,000 | +41.2% | 1,831 | +67.8% | 0.00% | – |
| Q3 2020 | $34,000 | +25.9% | 1,091 | 0.0% | 0.00% | – |
| Q2 2020 | $27,000 | +12.5% | 1,091 | -4.3% | 0.00% | – |
| Q1 2020 | $24,000 | +41.2% | 1,140 | +53.2% | 0.00% | – |
| Q4 2019 | $17,000 | +1600.0% | 744 | +1590.9% | 0.00% | – |
| Q3 2019 | $1,000 | – | 44 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |